From Analysis:
The debate focused on therapeutic targets but did not address how to identify patients in the optimal treatment window. Without reliable biomarkers for microglial priming, clinical translation of these hypotheses remains problematic. Source: Debate session sess_SDA-2026-04-04-gap-20260404-microglial-priming-early-ad (Analysis: SDA-2026-04-04-gap-20260404-microglial-priming-early-ad)
Site-specific glycosylation patterns on circulating TREM2 ectodomain fragments reflect the metabolic state and activation history of CNS microglia, serving as predictive biomarkers for anti-neuroinflammatory therapeutic responses. The hypothesis posits that microglial priming states differentially regulate glycosyltransferase expression (particularly ST6GAL1, MGAT5, and FUT8), leading to distinct N-linked and O-linked glycan signatures on TREM2 ectodomains shed into circulation. Unlike CSF fragment ratios that require lumbar puncture, plasma glycan profiling via lectin arrays or mass spectrometry offers accessible monitoring of microglial functional states.
...No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["TREM2/ADAM10/17
Primary Target"]
B["Biological Process 1
Mechanistic Step A"]
C["Biological Process 2
Mechanistic Step B"]
D["Output Phenotype
Disease Effect"]
A --> B
B --> C
C --> D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Title: Distinguishing primed from dystrophic microglia using TSPO PET with compartmental modeling
Mechanism: TSPO expression increases with microglial activation, but quantitative metrics (distribution volume VT, binding potential BP) may reveal distinct kinetic signatures between surveillance (baseline), primed (heightened sensitivity), and fully activated states. Primed microglia may show intermediate TSPO availability.
**Target Gene/Prot
Specificity Crisis. TSPO is expressed on microglia, astrocytes, endothelial cells, and infiltrating peripheral immune cells. TSPO PET measures a composite signal from heterogeneous cell populations, making it fundamentally unable to distinguish microglial-specific priming states. Post-mortem validations correlating TSPO+ cells with disease progression cannot disentangle this cellular ambiguity for in vivo application.
The "Intermediate Signal" Problem. The hypo
The debate identified a fundamental translational gap: even validated microglial targets remain therapeutically inaccessible without biomarkers to define the treatment-eligible population. The biomarker hypotheses range from near-term clinical feasibility (Hypotheses 2, 5, 6) to speculative targets requiring extensive development (Hypotheses 4, 7). The integration of clinical pragmatism with mechanistic specificity determines which hypotheses merit prioritization.
| Hypothesi
No price history recorded yet
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
No knowledge graph edges recorded
biomarkers | 2026-04-06 | archived
No comments yet. Be the first to comment!